|1.||Borgohain, Rupam: 4 articles (11/2014 - 01/2012)|
|2.||Stocchi, F: 4 articles (02/2014 - 08/2004)|
|3.||Roach, Arthur: 3 articles (05/2013 - 04/2013)|
|4.||Schapira, Anthony H V: 3 articles (01/2012 - 09/2010)|
|5.||Fariello, R G: 3 articles (10/2006 - 08/2004)|
|6.||Kohn, Harold: 2 articles (02/2015 - 05/2010)|
|7.||Sardina, Marco: 2 articles (01/2015 - 01/2013)|
|8.||Lucini, Valentina: 2 articles (09/2014 - 01/2012)|
|9.||Giuliani, Rodolfo: 2 articles (09/2014 - 01/2012)|
|10.||Stocchi, Fabrizio: 2 articles (09/2014 - 01/2012)|
|1.||Parkinson Disease (Parkinson's Disease)
01/01/2012 - "A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients."
12/01/2015 - "Safinamide (Xadago™) is an oral α-aminoamide derivative marketed for the treatment of Parkinson's disease (PD). "
12/01/2015 - "Clinical pharmacology review of safinamide for the treatment of Parkinson's disease."
04/01/2015 - "Safinamide (Xadago(®)) is an oral α-aminoamide derivative developed by Newron for the treatment of Parkinson's disease (PD). "
11/01/2014 - "Safinamide for the treatment of Parkinson's disease."
01/01/2015 - "While no statistically significant difference in mean DRS scores was seen between safinamide and placebo in the original study population, the present post-hoc analysis helps to provide a meaningful interpretation of the long-term effects of safinamide on dyskinesia. "
01/01/2015 - "This post-hoc analysis further characterized the effects of safinamide on dyskinesia in mid- to late-stage PD patients. "
09/01/2014 - "Change in Dyskinesia Rating Scale was not significantly different in safinamide versus placebo groups, despite decreased mean total Dyskinesia Rating Scale with safinamide compared with an almost unchanged score in placebo. "
02/01/2014 - "At week 24, mean ± SD increases in total on time with no or nontroublesome dyskinesia were 1.36 ± 2.625 hours for safinamide 100 mg/day, 1.37 ± 2.745 hours for safinamide 50 mg/day, and 0.97 ± 2.375 hours for placebo. "
09/01/2014 - "This 2-year, controlled study of add-on safinamide in mid-to-late Parkinson's disease with motor fluctuations, although not demonstrating an overall difference in dyskinesias between patients and controls, showed improvement in dyskinesia in patients at least moderately dyskinetic at baseline. "
05/01/1998 - "These results indicate that PNU-151774E is an anticonvulsant effective in various seizure models with a wide therapeutic window, and with a low potential to induce tolerance and locomotor or cognitive side effects."
11/01/1999 - "The activity shown by PNU-151774E at doses similar to those that are active in models of generalized seizures indicates that PNU-151774E would also have potential efficacy in the treatment of complex partial seizures."
11/01/1999 - "PNU-151774E (1, 10, 30 mg/kg; i.p.) reduced the duration of behavioral seizures significantly and dose-dependently at doses starting from 1 mg/kg. Higher doses significantly reduced seizure severity and afterdischarge duration. "
11/01/1999 - "Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures."
02/18/2015 - "The functionalized amino acid, lacosamide ((R)-2), and the α-aminoamide, safinamide ((S)-3), are neurological agents that have been extensively investigated and have displayed potent anticonvulsant activities in seizure models. "
|4.||Parkinsonian Disorders (Parkinsonism)
02/01/2014 - "The addition of safinamide 50 mg/day or 100 mg/day to l-dopa in patients with PD and motor fluctuations significantly increased total on time with no or nontroublesome dyskinesia, decreased off time, and improved parkinsonism, indicating that safinamide improves motor symptoms and parkinsonism without worsening dyskinesia."
|5.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
04/01/2013 - "Safinamide provided significant protection against neurological deficit and axonal degeneration in experimental autoimmune encephalomyelitis, even when administration was delayed until after the onset of neurological deficit. "
04/01/2013 - "The findings show that safinamide is effective in protecting axons from degeneration in experimental autoimmune encephalomyelitis, and that this effect is likely to involve a direct effect on microglia that can result in a less activated phenotype. "
04/01/2013 - "To clarify which property of safinamide was likely to be involved in the suppression of the innate immune cells, the action of safinamide on microglia/macrophages was compared with that of the classical sodium channel blocking agent, flecainide, which has no recognized monoamine oxidase B activity, and which has previously been shown to protect the white matter in experimental autoimmune encephalomyelitis. "
|1.||Levodopa (L Dopa)
|3.||Monoamine Oxidase (MAO)
|4.||Dopamine Agonists (Dopamine Agonist)
|5.||Glutamic Acid (Glutamate)
|7.||levodopa drug combination carbidopa (Nakom)
|8.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|1.||Investigational Therapies (Experimental Therapy)
|2.||Drug Therapy (Chemotherapy)